INVITED SPEAKERS: I-1: MESENCHYMAL STEM CELL THERAPY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ABDI R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Cell Journal (Yakhteh) Year:2011 | Volume:13 | Issue:SUPPLEMENT 2 Page(s): 4-4

Download Full-Text

View:

291

Download:

Cites:

Information Journal Paper

Title

INVITED SPEAKERS: I-1: MESENCHYMAL STEM CELL THERAPY

Author(s)

ABDI R. | Issue Writer Certificate

Keywords

MESENCHYMAL STEM CELL

STEM CELL THERAPY

TYPE 1 DIABETES

Abstract

Human clinical trials in TYPE 1 DIABETES (T1D) patients are presently underway using MESENCHYMAL STEM CELLs (MSCs) without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in non-obese diabetic (NOD) mice. In comparison to NOD-, BALB/c-MSC were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e. NOR or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NOD-MSC. Administration of BALB/c- MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p=0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NOD-MSCtreated mice, which were uniquely observed in this setting (i.e. no tumors were present with BALB/c- or NOR-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSCbased therapies for T1D and potentially, for other autoimmune disorders.

Cites

No record.

References

No record.

Cite

APA: Copy

ABDI, R.. (2011). INVITED SPEAKERS: I-1: MESENCHYMAL STEM CELL THERAPY. CELL JOURNAL (YAKHTEH), 13(SUPPLEMENT 2), 4-4. SID. https://sid.ir/paper/573382/en

Vancouver: Copy

ABDI R.. INVITED SPEAKERS: I-1: MESENCHYMAL STEM CELL THERAPY. CELL JOURNAL (YAKHTEH)[Internet]. 2011;13(SUPPLEMENT 2):4-4. Available from: https://sid.ir/paper/573382/en

IEEE: Copy

R. ABDI, “INVITED SPEAKERS: I-1: MESENCHYMAL STEM CELL THERAPY,” CELL JOURNAL (YAKHTEH), vol. 13, no. SUPPLEMENT 2, pp. 4–4, 2011, [Online]. Available: https://sid.ir/paper/573382/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops